The Good, Bad, and Ugly of Addiction
Saturday, August 3, 2013
UK Chandler Medical Center—Pavilion A Auditorium
Lexington, KY

Overview
Substance use disorders are common medical disorders of which all health care providers should be aware, have basic knowledge about, and practice competence in order to screen, refer, and/or treat. Prescribers as well as non-prescribing health care providers need training in substance use disorders, urine drug screening and testing, and therapeutic use of KASPER. The latter two are practice behaviors that are required by law for prescribers of several controlled substances in Kentucky. This conference has been approved by the KBML as meeting the statutory requirements of HB1.

Target Audience
This activity is designed for prescribers of controlled substances including physicians, nurse practitioners, and dentists and any other interested health care professionals.

Registration
There is no charge for this event; however, registration is required. To register online, visit www.cecentral.com/live/6837. For more information, contact CE Central at 859-257-5320 or support@cecentral.com. Please indicate any special accommodation or diet needed to attend this activity when registering.

Cancellation
We reserve the right to cancel or make substitutions to this activity. If it becomes necessary for you to cancel your registration, please call (859) 257-5320.
Objectives

Upon completion of this educational activity, you will be able to:

- Discuss the prevalence and incidence of injection drug abuse and its relationship to HIV, hepatitis C (HCV), and herpes simplex-2 virus (HSV-2)
- Review the ASAM criteria Levels of Care for treatment
- Discuss the total costs and consequences of prescription drug abuse on medical care, total stakeholder burden, and the treatment costs of prescription drug abuse
- Review why both buprenorphine and methadone are on the World Health Organization (WHO) list of essential medications
- Compare and contrast pharmacology of buprenorphine and methadone
- List common pitfalls for prescribing both medications (with case examples)
- Access the SAMHSA treatment locator and national mentoring programs sponsored by SAMHSA for addiction and pain [i.e., the PCSS-O (opioid) and the PCSS-B (buprenorphine)]
- Review neonatal and maternal outcomes with vs without medication assisted treatment and maintenance vs. detox among pregnant opioid dependent women
- Review birth control options for the purpose of educating physicians whose patients are not currently pregnant and not wanting to become pregnant
- Describe the impact of maternal drug abuse on the fetus and neonate
- Identify the clinical presentation of neonatal drug withdrawal
- Interpret and verify a KASPER report
- Have the difficult conversations with patients about unexpected KASPER report results
- Review metabolism of commonly prescribed pain pills that can affect interpretation of urine drug test and give case examples of common misinterpreted results
- Explain the differences between urine screens vs. tests
- Describe how substance abuse presents in the emergency department
- Describe substance abuse as a co-factor in other medical conditions
- Identify aberrant patient behaviors in the emergency department
- Review the pharmacology and pharmacokinetics of naloxone
- Describe the administration of naloxone injection intranasally
- Describe regional experiences with adopting naloxone overdose prevention programs
- Describe the legal requirements for prescribers and dispensers of naloxone for opioid overdose prevention
- Describe patient and family counseling necessary for fulfilling naloxone prescriptions when prescribing for overdose prevention

The University of Kentucky is an Equal Opportunity Employer

Daniel Wermeling, PharmD, FCCP, FASHP
Professor, Pharmacy Practice & Science—UK College of Pharmacy
President, AntiOp, Inc., Lexington, KY
dwermel@uky.edu

Dr. Wermeling received his PharmD degree from the University of Kentucky College of Pharmacy. In 1985 he completed a 2-year clinical pharmacy residency at the AB Chandler Medical Center in Lexington, KY. In 1987 he completed a drug development fellowship under Dr. Thomas Foster at the University of Kentucky College of Pharmacy.

His background includes studying the clinical pharmacology of analgesic delivery systems. He is responsible for the College of Pharmacy and the Interdisciplinary Pain Management Training Programs at UK. His current research interest is in the nasal delivery of naloxone as a needle-free delivery method of the opioid antidote. He is developing a unit-dose naloxone nasal spray product, currently NIDA funded, and in FDA development. He is responsible for the Interdisciplinary Pain Management Program and the pain management in the College of Pharmacy.

Ryan Stanton, MD
President, Kentucky American College of Emergency Physicians
Medical Director, Lexington Fire/EMS
Director, PR, Media, & Education, MESA Medical Group
ryanstanton@gmail.com

Dr. Stanton earned a MD from East Tennessee State University Quillen College of Medicine in Johnson City. He completed residency at the University of Kentucky Chandler Medical Center.

Dr. Stanton is certified by the American Board of Emergency Medicine.

Faculty Disclosure

All planners, speakers, authors and reviewers involved with content development for continuing education activities sponsored by the UK College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the activity. Detailed disclosures will be included in participant materials or given prior to the start of the activity.
Jonathan Weeks, MD  
University of Louisville Health Care Outpatient Center  
jonathan.weeks@louisville.edu

Dr. Weeks earned an MD from the University of Kentucky College of Medicine in Lexington. He completed internship and residency in obstetrics and gynecology at the Naval Hospital in San Diego, California. He completed a fellowship in maternal-fetal medicine at the Long Beach Memorial Medical Center-University of California Irvine.

He is certified by the American board of Obstetrics and Gynecology-Specialty Certification in Maternal-Fetal Medicine. His areas of interest are Preterm Labor, Ultrasound Diagnosis, Thrombocytopenia/ITP and Pregnancy, and Rheumatoid Arthritis and Pregnancy. His professional affiliations include American Congress of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, Greater Louisville Medical Society, Kentucky Medical Association, and the University of Kentucky College of Medicine Alumni Association.

Lori Devlin-Phinney, DO, MHA  
Asst. Prof. Pediatrics — University of Louisville School of Medicine  
l0devl01@louisville.edu

Dr. Devlin-Phinney earned an MD from the Des Moines University-College of Osteopathic Medicine. She completed internship and residency in pediatrics at Doctors Hospital in Columbus. She completed fellowship training in neonatal-perinatal medicine at Kosair Children's Hospital in Louisville. She holds an MHA from the University of Osteopathic Medicine in Des Moines.
Faculty

Van Ingram, Executive Director
Kentucky Office of Drug Control Policy
van.ingram@ky.gov

Van joined ODCP in November 2004, shortly after it was created with the mission of coordinating Kentucky’s substance abuse efforts in enforcement, treatment and prevention/education.

Ingram served with the Maysville Police Department for more than 23 years, the last six as its chief. He is a former president of the Kentucky Association of Chiefs of Police, and was named “Kentucky Chief of the Year” in 2001. He is a former recipient of the Governor’s Award for Outstanding Contribution to Law Enforcement as well as the Melvin Shein Award for distinguished service to Kentucky law enforcement.

In addition, he is a frequent speaker on a variety of substance abuse issues and has presented to numerous groups and national organizations on the topic of electronically monitoring pseudoephedrine sales.

Jennifer Havens, PhD, MPH
Associate Professor, UK Dept of Behavioral Science & Center on Drug and Alcohol Research
Jennifer.havens@uky.edu

Dr. Havens is an epidemiologist with an appointment in the Center on Drug and Alcohol Research. She earned a MPH and a PhD from the Johns Hopkins Bloomberg School of Public Health.

Her primary research interests include the epidemiology of prescription opioid abuse in rural Appalachia, the co-morbidity of substance and mental disorders, and HIV and other infectious complications of drug use.

Kelly Clark, MD, MBA
Chief Medical Officer
Behavioral Health Group, Dallas, TX
drkjclark@yahoo.com

A Phi Beta Kappa graduate of Coe College in Cedar Rapids, Iowa, Kelly holds an MD from the University of Wisconsin and an MBA with Additional Certification in Health Sector Management from the Fuqua School of Business at Duke University. Dr. Clark is a Fellow of the American Society of Addiction Medicine, where she serves as a Director, and is a Distinguished Fellow of the American Psychiatric Association.

Dr. Clark has a wide breadth and depth of both clinical and administrative experience. She has practiced addiction medicine and psychiatry throughout the continuum of care, and taught addiction treatment as a faculty member of the University of Massachusetts. She has worked to integrate medical and behavioral health care management as Medical Director at CDPHP. She serves as President of the Kentucky Society of Addiction Medicine, where she has practiced medicine for several years and served as Medical Director of a number of Opioid Treatment Programs.

Michelle Lofwall, MD
Associate Professor, UK Depts. Of Behavioral Science & Psychiatry & Center on Drug & Alcohol Research
michelle.lofwall@uky.edu

Dr. Lofwall completed residency training in Psychiatry and a clinical research fellowship in behavioral pharmacology at Johns Hopkins University. She now is an Associate Professor of Behavioral Science and Psychiatry in the Center on Drug and Alcohol Research at the University of Kentucky.

She is a strong addiction treatment advocate and has an active outpatient addiction treatment practice. She also teaches residents, medical students, and other allied health professionals about treatment of substance use disorders. She spends the majority of her time engaged in clinical research aimed at improving substance abuse treatment and has a particular interest in risk management educational programs to prevent diversion and misuse of controlled prescription medications.

Dr. Lofwall is the current President of the Kentucky Chapter of the American Society of Addiction Medicine, Associate Editor of the American Academy of Addiction Psychiatry newsletter, and member of the Governor’s KASPER Advisory Council.